Driving innovation for rare skin cancers: utilizing common tumours and machine learning to predict immune checkpoint inhibitor response

Metastatic Merkel cell carcinoma (MCC) and cutaneous squamous cell carcinoma (cSCC) are rare and both show impressive responses to immune checkpoint inhibitor treatment. However, at least 40% of patients do not respond to these expensive and potentially toxic drugs. Development of predictive biomark...

Descripción completa

Detalles Bibliográficos
Autores principales: Hooiveld-Noeken, J.S., Fehrmann, R.S.N., de Vries, E.G.E., Jalving, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9216707/
https://www.ncbi.nlm.nih.gov/pubmed/35755000
http://dx.doi.org/10.1016/j.iotech.2019.11.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9216707/
https://www.ncbi.nlm.nih.gov/pubmed/35755000
http://dx.doi.org/10.1016/j.iotech.2019.11.002

Ejemplares similares